Therefore, we believe the results of the current study are a snapshot of the potential real-world impact of PSMA PET if incorporated into routine clinical practice and confirm the observations from prior trials on the impact of PET on the outcomes of men with biochemical failure after primary therapy for prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.